AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03128528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor.
Study NCT00569192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.135mg MAP0010
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
Study NCT00569192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg MAP0010
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
Study NCT00569192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered by nebulization twice daily for 12 weeks
Study NCT04765410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EUS FNA (endoscopic ultrasound fine needle aspiration)
Description: Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
Study NCT00076258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSRI + PHD
Description: Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
Study NCT03322436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HeartLinc kit
Description: Samples are collected and analyzed afterwards
Study NCT04622202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: oral capsule pregabalin 150 mg.
Study NCT04622202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: oral placebo in the form of oral multivitamin capsule.
Study NCT02111681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso Beacon Implantation
Description: Bronchoscopic Calypso Beacon Implantation
Study NCT02518841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermaWedge TM
Description: ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
Study NCT02518841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermaWedge TM
Description: ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
Study NCT02518841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Achilles Tendon Stretching
Description: Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
Study NCT02518841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Achilles Tendon Stretching
Description: Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
Study NCT03527862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment according to lung ultrasonography
Description: Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
Study NCT01824121 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: stem cell therapy
Description: Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
Study NCT01824121 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem cell therapy
Description: Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
Study NCT03193034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Total Knee Arthroplasty
Description: Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
Study NCT02194764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and 2-butanol
Description: 50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
Study NCT02194764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)
Description: a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
Study NCT01683877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FloSeal application
Description: After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
Study NCT01683877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery
Description: After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
Study NCT01583270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan
Description: Porridge rich in arabinoxylan
Study NCT01583270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rye kernel
Description: Porridge made of rye kernels
Study NCT01583270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan and rye kernels
Description: Porridgde made of rye kernels and arabinoxylan
Study NCT01583270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Semolina
Description: Semoline porridge. control meal.
Study NCT04122755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
Study NCT02910843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: * Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.
Study NCT04122755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine sublingual film
Description: ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
Study NCT02910843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: • Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
Study NCT02910843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
Study NCT02910843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
Study NCT01740154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Undergo TMS
Study NCT01740154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electromyography
Description: Undergo EMG
Study NCT01740154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT01740154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT03130283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Hospitalization
Description: Visit every 24 hours
Study NCT03130283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Hospitalization
Description: No intervention
Study NCT01844973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M518101
Description: Proper quantity twice a day
Study NCT01844973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Proper quantity twice a day
Study NCT03887156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Description: Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
Study NCT03293446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urinary acidification test
Description: Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
Study NCT03293446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary acidification test
Description: Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
Study NCT00618852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: The dose of furosemide will be 1 mg/kg by intravenous bolus injection
Study NCT02215213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D
Study NCT02215213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D Supplement
Study NCT02575950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO43204
Study NCT02575950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05235841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Acupressure is a complementary and supportive approach used in symptom management.
Study NCT02924350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days).
Study NCT02924350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days).
Study NCT03836170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
Study NCT04755023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
Description: Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
Study NCT03464383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
Study NCT03464383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Psychiatry
Description: Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
Study NCT03464383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey only
Description: One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
Study NCT01359683 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dataq Instruments DI-158
Description: Data Acquisition Device (connects to room instrumentation)
Study NCT03304613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management
Description: Already noted.
Study NCT03304613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience through Innovative Self-Management
Description: Already noted.
Study NCT00990262 — intervention group
Intervention type: RADIATION
Intervention: Cardiac Computed Tomography
Description: 1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds.
Study NCT02827578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin
Study NCT02827578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin
Study NCT02827578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin
Study NCT02827578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin placebo
Description: Solifenacin placebo
Study NCT01722864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study NCT03747614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone
Description: Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452
Study NCT03747614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Slit-Lamp Biomicroscopy
Description: A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
Study NCT00746785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Olanzapine
Description: 2.5 mg
Study NCT00746785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg Olanzapine
Description: 5 mg
Study NCT00746785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03308747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Instantized Whey Protein Isolate
Description: 0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
Study NCT03308747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Instantized Whey Protein Isolate
Description: 0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
Study NCT03200236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Telephone Counseling (8 sessions) with nicotine replacement
Description: Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
Study NCT03200236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care: Telephone counseling (3 sessions) with nicotine replacement
Description: Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
Study NCT03475056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-Marburg vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
Study NCT03948464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow release oral morphine (SROM)
Description: Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
Study NCT03948464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
Study NCT00618852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 mg/kg by intravenous bolus injection
Study NCT02495818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
Study NCT02495818 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline solution
Description: Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
Study NCT02495818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homemade exercises
Description: Codman and Hughston exercises.
Study NCT02495818 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Homemade exercises
Description: Codman and Hughston exercises.
Study NCT04081831 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Follow clinical administration
Study NCT01458951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 10 mg oral BID
Study NCT01458951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral BID
Study NCT02535169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education and Coaching Strategy
Description: Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
Study NCT02535169 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary consult
Description: A routine clinic-based dietary consult will be performed (approximately 1-hour).